- Home
- HUMA vs DBL Comparison
HUMA vs DBL Comparison
Compare HUMA & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMA
- DBL
- Stock Information
- Founded
- HUMA 2004
- DBL 2011
- Country
- HUMA United States
- DBL United States
- Employees
- HUMA N/A
- DBL N/A
- Industry
- HUMA Biotechnology: Pharmaceutical Preparations
- DBL
- Sector
- HUMA Health Care
- DBL
- Exchange
- HUMA Nasdaq
- DBL Nasdaq
- Market Cap
- HUMA 324.0M
- DBL 292.0M
- IPO Year
- HUMA N/A
- DBL N/A
- Fundamental
- Price
- HUMA $1.67
- DBL $15.47
- Analyst Decision
- HUMA Strong Buy
- DBL
- Analyst Count
- HUMA 7
- DBL 0
- Target Price
- HUMA $10.00
- DBL N/A
- AVG Volume (30 Days)
- HUMA 7.5M
- DBL 61.0K
- Earning Date
- HUMA 11-07-2025
- DBL 01-01-0001
- Dividend Yield
- HUMA N/A
- DBL 8.67%
- EPS Growth
- HUMA N/A
- DBL N/A
- EPS
- HUMA N/A
- DBL N/A
- Revenue
- HUMA $818,000.00
- DBL N/A
- Revenue This Year
- HUMA N/A
- DBL N/A
- Revenue Next Year
- HUMA $1,468.13
- DBL N/A
- P/E Ratio
- HUMA N/A
- DBL N/A
- Revenue Growth
- HUMA N/A
- DBL N/A
- 52 Week Low
- HUMA $1.15
- DBL $13.75
- 52 Week High
- HUMA $6.77
- DBL $15.70
- Technical
- Relative Strength Index (RSI)
- HUMA 47.73
- DBL 47.08
- Support Level
- HUMA $1.65
- DBL $15.36
- Resistance Level
- HUMA $1.78
- DBL $15.58
- Average True Range (ATR)
- HUMA 0.10
- DBL 0.18
- MACD
- HUMA -0.01
- DBL -0.01
- Stochastic Oscillator
- HUMA 23.73
- DBL 30.86
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.